Evaluation of the Antiviral Effect of Rifabutin in AIDS-Related Complex

Rifabutin (ansamycin LM 427) is a rifamycin antibiotic with strong inhibitory activity in vitro against Mycobacterium avium-intracellulare complex (MAC) and M. tuberculosis . It is a spiropiperidyl derivative of rifamycin S. Recently rifabutin has been suggested to be useful in the treatment or prev...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1989-06, Vol.159 (6), p.1115-1118
Main Authors: Torseth, John, Bhatia, Gulshan, Harkonen, Scott, Child, Carroll, Skinner, Michael, Robinson, William S., Blaschke, Terrence F., Merigan, Thomas C.
Format: Article
Language:English
Subjects:
Adult
AIDS
AIDS-Related Complex - drug therapy
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antibodies
Antigens
Antiviral agents
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Biological and medical sciences
Concise Clinical and Laboratory Communications
Dosage
Experimentation
Fever
HIV
HIV - drug effects
HIV Antigens - analysis
HIV Core Protein p24
Humans
Infections
Lymphocytes
Male
Medical sciences
Pharmacology. Drug treatments
Retroviridae Proteins - analysis
Rifabutin
Rifamycins
Rifamycins - adverse effects
Rifamycins - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rifabutin (ansamycin LM 427) is a rifamycin antibiotic with strong inhibitory activity in vitro against Mycobacterium avium-intracellulare complex (MAC) and M. tuberculosis . It is a spiropiperidyl derivative of rifamycin S. Recently rifabutin has been suggested to be useful in the treatment or prevention of AIDS, because it inhibited reverse transcriptase activity in 7-d cultures of human immunodeficiency virus (HIV) in lymphocytes. The authors studied escalated dosages of this drug in patients with HIV infection, most of whom had detectable circulating HIV p24 antigen, which has been shown to decrease with therapeutic doses of zidovudine or dideoxycytidine.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/159.6.1115